Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

Publication | Closed Access

DOI

150

Citations

References

2016

Year

Nadia Harbeck, Chiun‐Sheng Huang, Sara A. Hurvitz, Dah‐Cherng Yeh, Zhimin Shao, Seock‐Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem,

The Lancet Oncology

Breast OncologyPrevious Trastuzumab TreatmentMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyLux-breast 1Cancer TreatmentOncologyVinorelbine Versus Trastuzumab